Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06651489 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Guselkumab in Treating Hailey Hailey Disease
A Phase 2 study of Hailey Hailey Disease, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06651489 is a Phase 2 study of Hailey Hailey Disease that is actively recruiting participants, run by Yale University. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06651489, a Phase 2 study of Hailey Hailey Disease, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Hailey-Hailey disease (HHD) is a debilitating genetic skin disorder, affecting mainly body folds with erythema and painful erosions and blisters. Histopathological findings include epidermal hyperplasia, suprabasilar clefting, dyskeratosis and acantholysis of keratinocytes. A final diagnosis of HHD is usually confirmed based on clinical and histopathological findings in line with genetic testing. Several treatment options have been proposed for this chronic and disabling disorder, however, there is no reproducibly effective therapeutic for it. The primary objective is to evaluate the treatment response of guselkumab. Single-center, non-randomized, single-arm, open-label, phase II trial to evaluate the efficacy and safety of guselkumab for the treatment of patients with HHD.
Conditions Studied
Interventions
- DRUG Guselkumab
Study Locations (1)
Connecticut
- Church Street Research Unit, Yale Center for Clinical Investigation - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-03-13 |
| Est. Completion | 2026-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06651489
The ClinicalTrials.gov registry entry for NCT06651489 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hailey Hailey Disease appearing as the primary indexed condition, and to 1 intervention - of which Guselkumab is the first listed.
NCT06651489 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT06651489 about?
NCT06651489 is a clinical study titled "Efficacy of Guselkumab in Treating Hailey Hailey Disease". Hailey-Hailey disease (HHD) is a debilitating genetic skin disorder, affecting mainly body folds with erythema and painful erosions and blisters. Histopathological findings include epidermal hyperplasia, suprabasilar clefting, dyskeratosis and acantholysis of keratinocytes. A final diagnosis of HHD ...
What is the current status of trial NCT06651489?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2025-03-13. Estimated completion is 2026-04.
What conditions does trial NCT06651489 study?
This clinical trial studies the following conditions: Hailey Hailey Disease.
What interventions are being tested in trial NCT06651489?
The interventions under investigation include: Guselkumab (DRUG).
Who is sponsoring clinical trial NCT06651489?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06651489 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.